Compare OSBC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | LBRX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 2025 |
| Metric | OSBC | LBRX |
|---|---|---|
| Price | $24.97 | $42.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $23.50 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 377.8K | 238.3K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $24.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.65 | $13.40 |
| 52 Week High | $26.06 | $50.16 |
| Indicator | OSBC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 43.01 |
| Support Level | $24.93 | $22.85 |
| Resistance Level | $25.95 | $49.74 |
| Average True Range (ATR) | 0.48 | 2.06 |
| MACD | -0.10 | -0.95 |
| Stochastic Oscillator | 33.96 | 17.85 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.